SG11201705361PA - Acc inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease - Google Patents

Acc inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease

Info

Publication number
SG11201705361PA
SG11201705361PA SG11201705361PA SG11201705361PA SG11201705361PA SG 11201705361P A SG11201705361P A SG 11201705361PA SG 11201705361P A SG11201705361P A SG 11201705361PA SG 11201705361P A SG11201705361P A SG 11201705361PA SG 11201705361P A SG11201705361P A SG 11201705361PA
Authority
SG
Singapore
Prior art keywords
treatment
combination therapy
liver disease
fatty liver
alcoholic fatty
Prior art date
Application number
SG11201705361PA
Other languages
English (en)
Inventor
Geraldine C Harriman
Rosana Kapeller-Libermann
William F Westlin
H James Harwood
Original Assignee
Gilead Apollo Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Apollo Llc filed Critical Gilead Apollo Llc
Publication of SG11201705361PA publication Critical patent/SG11201705361PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201705361PA 2015-01-09 2016-01-08 Acc inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease SG11201705361PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562101726P 2015-01-09 2015-01-09
PCT/US2016/012673 WO2016112305A1 (en) 2015-01-09 2016-01-08 Acc inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease

Publications (1)

Publication Number Publication Date
SG11201705361PA true SG11201705361PA (en) 2017-08-30

Family

ID=56356482

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201705361PA SG11201705361PA (en) 2015-01-09 2016-01-08 Acc inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease

Country Status (13)

Country Link
US (2) US20180021341A1 (ru)
EP (2) EP3242722A4 (ru)
JP (2) JP2018501276A (ru)
KR (1) KR20170102299A (ru)
CN (1) CN107106873A (ru)
AU (1) AU2016205138A1 (ru)
BR (1) BR112017014341A2 (ru)
CA (1) CA2972919A1 (ru)
EA (2) EA201892625A1 (ru)
HK (2) HK1243369A1 (ru)
MX (1) MX2017008844A (ru)
SG (1) SG11201705361PA (ru)
WO (1) WO2016112305A1 (ru)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE049976T2 (hu) 2005-12-28 2020-11-30 Vertex Pharma N-[2,4-bisz(1,1-dimetil-etil)-5-hidroxi-fenil]-1,4-dihidro-4-oxo-kinolin-3-karboxamid amorf alakjának gyógyászati kompozíciói
TWI625121B (zh) 2009-07-13 2018-06-01 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
WO2011140441A2 (en) 2010-05-06 2011-11-10 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
US11571431B2 (en) 2013-12-04 2023-02-07 Galmed Research And Development Ltd Aramchol salts
EP3712254A1 (en) 2014-05-28 2020-09-23 Children's Hospital Medical Center Methods and systems for converting precursor cells into gastric tissues through directed differentiation
US11584916B2 (en) 2014-10-17 2023-02-21 Children's Hospital Medical Center Method of making in vivo human small intestine organoids from pluripotent stem cells
NZ738525A (en) 2015-07-06 2019-03-29 Gilead Sciences Inc Cot modulators and methods of use thereof
HUE053175T2 (hu) 2015-11-25 2021-06-28 Gilead Apollo Llc ACC-gátló észterek és azok alkalmazása
EP3380480B1 (en) * 2015-11-25 2022-12-14 Gilead Apollo, LLC Pyrazole acc inhibitors and uses thereof
IL243707A0 (en) 2016-01-20 2016-05-01 Galmed Res And Dev Ltd Treatment to regulate the microbiota in the intestine
CA3155220C (en) 2016-03-02 2024-01-16 Gilead Apollo, Llc Solid forms of a thienopyrimidinedione acc inhibitor and methods for production thereof
EP4177335A1 (en) 2016-05-05 2023-05-10 Children's Hospital Medical Center Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same
CA2968836A1 (en) 2016-06-13 2017-12-13 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
ES2921432T3 (es) 2016-06-13 2022-08-25 Gilead Sciences Inc Derivados de azetidina como moduladores de FXR (NR1H4)
CN117229994A (zh) 2016-11-04 2023-12-15 儿童医院医学中心 肝类器官疾病模型以及其制备和使用方法
US11197870B2 (en) 2016-11-10 2021-12-14 Galmed Research And Development Ltd Treatment for hepatic fibrosis
MX2019005533A (es) * 2016-11-10 2020-02-07 Galmed Res And Development Ltd Tratamiento de la fibrosis.
KR20190083660A (ko) * 2016-11-10 2019-07-12 갈메드 리서치 앤드 디벨롭먼트 리미티드 비-알코올성 지방 간질환 환자에 있어서 섬유증의 억제
SG10202105768WA (en) 2016-12-05 2021-06-29 Childrens Hospital Med Ct Colonic organoids and methods of making and using same
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
CN108341830B (zh) * 2017-01-22 2021-03-02 广东东阳光药业有限公司 噻吩并嘧啶衍生物及其在药物中的应用
US11142531B2 (en) 2017-03-24 2021-10-12 Zhejiang Hisun Pharmaceutical Co., Ltd. Cyano substituted heteroarylpyrimidinone derivative, preparation method and use thereof
CA3056925A1 (en) * 2017-03-28 2018-10-04 Gilead Sciences, Inc. Methods of treating liver disease
ES2927019T3 (es) * 2017-03-28 2022-11-02 Gilead Sciences Inc Combinaciones terapéuticas para el tratamiento de enfermedades hepáticas
EP3609496A1 (en) * 2017-04-12 2020-02-19 Gilead Sciences, Inc. Methods of treating liver disease
EP3612175A1 (en) * 2017-04-18 2020-02-26 Genfit Combination of elafibranor or derivatives thereof with an anti-nash, anti-fibrotic or anti-cholestatic agent
EP3609523B1 (en) * 2017-04-24 2022-03-02 Tsinghua University Use of autoinducer-related pathway in inducing apoptosis and anti-infective therapy
WO2018236896A1 (en) * 2017-06-19 2018-12-27 Arena Pharmaceuticals, Inc. COMPOUNDS AND METHODS FOR THE TREATMENT OF NAFLD AND NASH
EP3655409B1 (en) 2017-07-17 2023-12-27 Nanjing Ruijie Pharmatech Co., Ltd. Novel compounds and their uses as acc inhibitors
US11186587B2 (en) * 2017-07-26 2021-11-30 Nanjing Sanhome Pharmaceutical Co., Ltd. Compound as ACC inhibitor and use thereof
CN109316601B (zh) * 2017-07-31 2021-11-09 武汉朗来科技发展有限公司 药物组合物及其用途
CN111406051A (zh) 2017-09-03 2020-07-10 安吉昂生物医药公司 作为rho相关卷曲螺旋激酶(rock)抑制剂的乙烯基杂环
US11033601B2 (en) * 2017-09-14 2021-06-15 The Regents Of The University Of Colorado, A Body Corporate Selective inhibition of V1b for treating fatty liver
TWI814744B (zh) * 2017-10-06 2023-09-11 美商基利科學股份有限公司 包含acc抑制劑之組合療法
CN114920818B (zh) * 2017-11-06 2024-02-27 深圳市图微安创科技开发有限公司 基于胃泌酸调节素类似物glp-1r/gcgr双靶点激动剂多肽治疗胆汁性肝硬化
CN107693514A (zh) * 2017-12-04 2018-02-16 威海贯标信息科技有限公司 一种鲁格列净组合物
CN111788195B (zh) 2018-01-31 2023-11-21 海帕瑞吉尼克斯股份有限公司 用于促进肝脏再生或减少或预防肝细胞死亡的蛋白激酶mkk4抑制剂
US20210113561A1 (en) * 2018-04-17 2021-04-22 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
WO2019209738A1 (en) * 2018-04-24 2019-10-31 Ph Pharma Co., Ltd. Use of neutrophil elastase inhibitors in liver disease
US11731968B2 (en) 2018-06-21 2023-08-22 Heparegenix Gmbh Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
CA3104246A1 (en) 2018-07-16 2020-01-23 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
WO2020037023A1 (en) * 2018-08-14 2020-02-20 Avolynt Method for treating primary sclerosing cholangitis
KR102614808B1 (ko) 2018-08-31 2023-12-19 화이자 인코포레이티드 Nash/nafld 및 관련 질환의 치료를 위한 조합물
KR20210057758A (ko) * 2018-09-06 2021-05-21 갈메드 리서치 앤드 디벨롭먼트 리미티드 간 질환을 치료하기 위한 병용 요법
CN110950884B (zh) * 2018-09-27 2024-03-26 上海翰森生物医药科技有限公司 含二并环类衍生物抑制剂、其制备方法和应用
JP2022513101A (ja) * 2018-11-20 2022-02-07 中国医▲薬▼研究▲開▼▲発▼中心有限公司 スピロ環系化合物及びその医薬用途
DK3911647T3 (da) 2019-01-15 2024-02-26 Gilead Sciences Inc Isoxazol-forbindelse som FXR-agonist og farmaceutiske sammensætninger, der omfatter en sådan
CN113439078B (zh) 2019-02-19 2024-04-23 吉利德科学公司 Fxr激动剂的固体形式
WO2020208205A1 (en) * 2019-04-10 2020-10-15 Genfit Combination therapy comprising compounds of formula (i) and glp-1 receptor agonists
JP2022532706A (ja) 2019-05-08 2022-07-19 アリゴス セラピューティクス，インコーポレーテッド ＴＨＲ－βの調節物質およびその使用方法
TWI770527B (zh) 2019-06-14 2022-07-11 美商基利科學股份有限公司 Cot 調節劑及其使用方法
EP3995498A4 (en) 2019-07-02 2023-03-01 Sunshine Lake Pharma Co., Ltd. THIENOPYRIMIDI DERIVATIVES WITH STEREO CONFIGURATION AND THEIR USE IN MEDICINE
WO2021018820A1 (en) 2019-07-29 2021-02-04 Heparegenix Gmbh Heteroaryl-substituted pyrazolo-pyridine protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
AR119594A1 (es) 2019-08-09 2021-12-29 Gilead Sciences Inc Derivados de tienopirimidina como inhibidores acc y usos de los mismos
CN110628810B (zh) * 2019-08-13 2022-06-28 浙江大学 一种提高植物光合效率的方法
KR20210027169A (ko) * 2019-08-30 2021-03-10 (주)셀트리온 비알콜성 지방간염(NASH, Nonalcoholic Steatohepatitis) 치료 또는 예방을 위한 약학 조성물
US20230105984A1 (en) 2019-12-23 2023-04-06 Svetlana Marukian Compositions and methods for the treatment of liver diseases and disorders
EP4090659B1 (en) 2020-01-15 2024-06-12 HepaRegeniX GmbH 3-benzoyl-1h-pyrrolo[2,3-b]pyridine derivatives as mkk4 inhibitors for treating liver diseases
JP2022058085A (ja) 2020-02-24 2022-04-11 ファイザー・インク ジアシルグリセロールアシルトランスフェラーゼ２阻害剤とアセチル－ＣｏＡカルボキシラーゼ阻害剤との組合せ
JP2021134211A (ja) 2020-02-24 2021-09-13 ファイザー・インク Ｎａｆｌｄ／ｎａｓｈおよび関連疾患の処置のための組合せ
CN115335055A (zh) * 2020-03-11 2022-11-11 东亚St株式会社 用于预防或治疗非酒精性脂肪性肝炎的药物组合物
AU2021249010A1 (en) 2020-03-30 2022-10-06 Gilead Sciences, Inc. Solid forms of (S)-6-(((1-(bicyclo[1.1.1]pentan-1-yl)-1H-1,2,3-triazol-4-yl)2-methyl-1-oxo-1,2- dihydroisoquinolin-5-yl)methyl)))amino)8-chloro-(neopentylamino)quinoline-3-carb onitrile a cot inhibitor compound
AU2021245924B2 (en) 2020-04-02 2024-02-29 Gilead Sciences, Inc. Process for preparing a Cot inhibitor compound
CN111407892A (zh) * 2020-04-08 2020-07-14 中国药科大学 Acsl4及其在nash中的应用
US11478533B2 (en) 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
JPWO2021235508A1 (ru) * 2020-05-21 2021-11-25
EP4000616A1 (en) 2020-11-17 2022-05-25 Inventiva Combination therapy for the treatment of a liver disease
WO2022192428A1 (en) 2021-03-11 2022-09-15 Gilead Sciences, Inc. Glp-1r modulating compounds
US20230079863A1 (en) 2021-03-29 2023-03-16 Gilead Sciences, Inc. Khk inhibitors
TW202304435A (zh) 2021-06-04 2023-02-01 美商基利科學股份有限公司 治療ｎａｓｈ之方法
TW202311256A (zh) 2021-06-18 2023-03-16 美商基利科學股份有限公司 用於治療ｆｘｒ誘發之搔癢之ｉｌ－３１調節劑
WO2023034381A1 (en) * 2021-08-31 2023-03-09 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Quantitative systems pharmacology methods for identifying therapeutics for disease states
WO2023047203A1 (en) * 2021-09-25 2023-03-30 Torrent Pharmaceuticals Ltd Combination of omzotirome and antidiabetic agent, antihypertensive agent or anti-dyslipidemic agent
WO2023090411A1 (ja) 2021-11-19 2023-05-25 塩野義製薬株式会社 心疾患または骨格筋の疾患の治療用医薬

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110288114A1 (en) * 2008-06-20 2011-11-24 Kinemed, Inc. Compositions for the treatment of fibrotic diseases or conditions
US20100113473A1 (en) * 2008-10-30 2010-05-06 Player Mark R Aryl amide compound as an acetyl coenzyme a carboxylase inhibitor
WO2012090219A2 (en) * 2010-12-31 2012-07-05 Jubilant Biosys Ltd. Thiazole compounds useful as acetyl-coa carboxylase (acc) inhibitors
SI2776038T1 (en) * 2011-11-11 2018-06-29 Gilead Apollo, Llc ACC INHIBITORS AND THEIR USE
EP2994141A4 (en) * 2013-05-10 2016-11-23 Nimbus Apollo Inc ACC-HEMMER AND USES THEREOF
CA2911818A1 (en) 2013-05-10 2014-11-13 Nimbus Apollo, Inc. Acc inhibitors and uses thereof
JP6417401B2 (ja) * 2013-05-10 2018-11-07 ギリアド アポロ， エルエルシー Ａｃｃ阻害剤及びその使用
AU2014262638A1 (en) * 2013-05-10 2015-11-26 Gilead Apollo, Llc ACC inhibitors and uses thereof

Also Published As

Publication number Publication date
CA2972919A1 (en) 2016-07-14
EA201791258A1 (ru) 2017-12-29
JP2020109130A (ja) 2020-07-16
EP3242722A1 (en) 2017-11-15
CN107106873A (zh) 2017-08-29
US20180021341A1 (en) 2018-01-25
KR20170102299A (ko) 2017-09-08
EP3242722A4 (en) 2018-07-11
BR112017014341A2 (pt) 2018-03-27
EA201892625A1 (ru) 2019-07-31
JP2018501276A (ja) 2018-01-18
US20190381045A1 (en) 2019-12-19
HK1246232A1 (zh) 2018-09-07
AU2016205138A1 (en) 2017-07-13
HK1243369A1 (zh) 2018-07-13
MX2017008844A (es) 2018-03-14
WO2016112305A1 (en) 2016-07-14
EP3597271A1 (en) 2020-01-22

Similar Documents

Publication Publication Date Title
HK1246232A1 (zh) 用於治療非酒精性脂肪肝病的acc抑制劑組合治療
IL253945A0 (en) kdm1a inhibitors to treat the disease
HK1247922A1 (zh) 用於治療癌症的吲哚胺2，3-雙加氧酶抑制劑
HK1247202A1 (zh) 用於治療癌症的化合物
HK1259458A1 (zh) 用於治療心血管疾病的吉卡賓組合
ZA201607740B (en) Treatment of the complications of chronic liver disease with caspase inhibitors
IL254266B (en) Glucosylceramide synthase inhibitors for the treatment of diseases
EP3132795A4 (en) Composition for preventing or treating fatty liver diseases
SG11202102684VA (en) Treatment for non-alcoholic fatty liver disease
EP3362053A4 (en) TREATMENT OF NON-ALCOHOLIC FATTYLENE OR NON-ALCOHOLIC STEATOHEPATITIS WITH 6-MERCAPTOPURIN WITH DELAYED RELEASE
ZA201805080B (en) Application of triacetyl-3-hydroxyphenyladenosine in preparation of pharmaceutical drug for preventing or treating non-alcoholic fatty liver disease
SI3302523T1 (sl) Sestavek za zdravljenje tkivnih lezij
GB201506654D0 (en) Formulations for inhibition of PCSK9 for the treatment of hypercholesterolemia
PL3484475T3 (pl) 1-Metylonikotynamid do leczenia choroby układu krążenia
PL3233074T3 (pl) Leczenie niealkoholowych stłuszczeniowych chorób wątroby
GB201411467D0 (en) 7-hydroxy cannabidiol (7-oh-cbd) for use in the treatment of non-alcoholic fatty liver disease (nafld)
PT3340975T (pt) Formulação para o tratamento de acne
ZA201706986B (en) Compositions for the treatment of kidney and/or liver disease
IL257689B (en) Pharmaceutical preparations and methods for treating diseases related to lack of oxygen
GB201622116D0 (en) Treatment of liver disease
HRP20181460T1 (hr) Derivati 4-okso-n-(4-hidroksifenil)retinamida kao terapeutska sredstva za liječenje karcinoma
PL3273997T3 (pl) Kompozycja do leczenia nieżytu nosa
GB201509781D0 (en) Non-alcoholic fatty liver disease